Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Desvenlafaxine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Desvenlafaxine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-001876-67 Sponsor Protocol Number: B2061030 Start Date*: 2016-07-27
    Sponsor Name:Pfizer Inc.
    Full Title: A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in th...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002064-34 Sponsor Protocol Number: B2061031 Start Date*: 2016-04-11
    Sponsor Name:Pfizer Inc.
    Full Title: A 6-MONTH, OPEN-LABEL, MULTI-CENTER, FLEXIBLE-DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED-RELEASE (DVS SR) TAB...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002067-14 Sponsor Protocol Number: 3151A6-2001 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Research
    Full Title: 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent O...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002063-13 Sponsor Protocol Number: B2061014 Start Date*: 2015-07-15
    Sponsor Name:Pfizer Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fluoxetine-Referenced Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Relea...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001875-32 Sponsor Protocol Number: B2061032 Start Date*: 2016-03-31
    Sponsor Name:Pfizer Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (DVS SR) In The Tre...
    Medical condition: Major Depressive Disorde
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000450-23 Sponsor Protocol Number: 3151A1-303-WW Start Date*: 2004-09-06
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000562-13 Sponsor Protocol Number: 3151A1-309-EU Start Date*: 2004-07-26
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Medical condition: Major depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002066-57 Sponsor Protocol Number: 3151A6-2000 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Research
    Full Title: Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Susta...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002704-41 Sponsor Protocol Number: 18498A Start Date*: 2020-03-13
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with par...
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LV (Completed) BG (Completed) SK (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005463-28 Sponsor Protocol Number: 3151A1-333-EU Start Date*: 2006-02-27
    Sponsor Name:Wyeth Pharmaceuticals France, Wyeth Research Division
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 FIXED DOSES (50 mg, 100 mg) OF DESVENLAFAXINE SUSTAINED-RELEASE TABLETS IN...
    Medical condition: Major Depressive Disorder in outpatients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) EE (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-005424-85 Sponsor Protocol Number: 3151A1-3360-WW Start Date*: 2009-07-15
    Sponsor Name:Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer company
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Di...
    Medical condition: The desvenlafaxine succinate sustained release formulation, DVS SR, is being used in development programs for the treatment of major depressive disorder (MDD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed) FR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-005022-45 Sponsor Protocol Number: 3151A1-321 Start Date*: 2005-05-02
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause
    Medical condition: Generally healthy, postmenopausal women of age 40 to 65 seeking treatment for hot flushes with last natural menstrual period (LNMP) completed at least 12 months prior to screening (if LNMP is uncer...
    Disease:
    Population Age: Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SE (Completed) FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004654-30 Sponsor Protocol Number: BHV4157-209 Start Date*: 2021-07-22
    Sponsor Name:Biohaven Pharmaceuticals, Inc
    Full Title: A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10002860 Anxiety disorder NEC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004653-69 Sponsor Protocol Number: BHV4157-303 Start Date*: 2021-09-27
    Sponsor Name:Biohaven Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10002860 Anxiety disorder NEC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005179-18 Sponsor Protocol Number: RGH-MD-75 Start Date*: 2012-03-12
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003251-37 Sponsor Protocol Number: ACP-103-054 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate R...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001192-17 Sponsor Protocol Number: ITI-007-501 Start Date*: 2021-11-24
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001212-29 Sponsor Protocol Number: ITI-007-502 Start Date*: 2022-01-23
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003073-33 Sponsor Protocol Number: MYL-1603N-3001 Start Date*: 2023-03-08
    Sponsor Name:Mylan Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Ant...
    Medical condition: Major Depression Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003448-58 Sponsor Protocol Number: 3101-304-002 Start Date*: 2021-02-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Pa...
    Medical condition: Episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004852 10082019 Episodic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed) HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:16:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA